A clinical utility risk-benefit analysis for HIV self-testing

As countries work to achieve the United Nation’s “90-90-90” testing and treatment targets, many countries are adopting WHO’s recommendation to offer HIVST as an additional HIV testing approach. Many self-testers can use an HIV rapid diagnostic test (RDT) correctly and achieve results similar to trained testers. Although HIVST does not provide an HIV-positive diagnosis some concern about potential false reactive and false non-reactive self-test results remain. Thus, we conducted a clinical utility risk benefit analysis to establish a minimum performance threshold for HIVST at which public health benefit can be achieved.